Discussion on the Clinical Follow-up Management of Fetal Soft Index Abnormalities by Ultrasound in District-level Maternal and Child Institutions
Objective: To explore the implementation effect and application value of clinical follow-up management of fetal soft index abnormalities detected by pregnancy ultrasound in district-level maternal and child health care institutions. Methods: 200 pregnant women who received fetal ultrasound examinations received by our center from January 2025 to December 2025 were selected as the research subjects, and standardized clinical follow-up management was implemented uniformly to collect statistics on the abnormal detection of various fetal ultrasound soft indicators, and to observe the outcome of abnormal indicators, follow-up completion and pregnancy outcomes. Results: A total of 67 fetal soft index abnormalities were detected among 200 second-trimester ultrasound examinations of pregnant women, with ventricular bright spots and renal pelvis separation accounting for the highest proportions. After systematic follow-up management, the follow-up completion rate of abnormal cases was 95.52%, the overall normalization rate of abnormal indicators was 89.55%, and the overall incidence of adverse pregnancy outcomes was low. Conclusion: District-level maternal and child institutions implement standardized special follow-up management for abnormal fetal ultrasound soft indicators, which can effectively improve the quality of follow-up completion, promote the regression and recovery of abnormal fetal soft indicators, reduce the probability of adverse pregnancy outcomes, and have important application significance for grassroots prenatal care work.
[1] Li J, 2025, Diagnostic Value of Ultrasound Soft Indicators Combined with Serological Indicators for Fetal Chromosomal Abnormalities in Early and Mid-Term Pregnant Women. Modern Medical Imaging, 34(9): 1740–1743.
[2] Lu Y, Zhang Z, Zhao J, et al., 2025, Clinical Significance of Mid-Trimester Ultrasound Soft Indicators for Fetal Chromosomal Abnormality Screening. Journal of Guizhou Medical University, 50(7): 1023–1028.
[3] Wang L, Geng X, Wu T, et al., 2025, Application of Chromosomal Microarray Analysis Technology in the Evaluation of Fetuses with Ultrasound Soft Index Abnormalities. Journal of Naval Medicine, 46(5): 518–520.
[4] Nan L, Ma Y, Zhang J, Shi X, 2025, Study on the Correlation Between CMA Combined with Karyotype Analysis and Fetal Ultrasound Soft Index Abnormalities in Elderly Pregnant Women. International Journal of Genetics, 48(1): 17–22.
[5] Lu L, Zhao Q, Wang R, et al., 2025, The Value of Prenatal Serological Screening Combined with Fetal Ultrasound Soft Indicators in the Diagnosis of Fetal Chromosomal Aneuploidy Abnormalities. Chinese Journal of Practical Medicine, 52(1): 76–79.
[6] Wang Y, Liu S, Kang L, 2024, Diagnostic Value of Fetal Ultrasound Screening Soft Indicators for Cardiac Structural Abnormalities at 11 to 14 Weeks of Pregnancy. Modern Medical Imaging, 33(11): 2155–2158.
[7] Zeng J, Luo L, Ren S, 2024, Consistency Analysis of Ultrasound Soft Index Abnormalities and Fetuses with Chromosomal Abnormalities in Early and Mid-Pregnancy (Amniocentesis). Imaging Research and Medical Applications, 8(20): 60–62 + 65.
[8] Li J, Yan H, Song J, Zhang Z, 2024, The Clinical Significance of Non-Invasive DNA Testing in Fetal Chromosome Screening for Single Ultrasound Soft Index Abnormalities. Heilongjiang Medical Science, 47(3): 49–52.
